Auditory monitoring in ototoxicity

Jacob-Corteletti, Lílian Cássia Bórnia; Aguiar, Fabrina Pavia; Tomiasi, Aline Aparecida; Tschoeke, Samira Natacha; Bitencourt, Raquel Fava de

doi:10.1016/s1808-8694(15)31053-3

Cited by 27 publications

(21 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our sample, we cannot exclude the possibility that the disease process, vascular alteration, radiation, or other unknown factors may have had an interactive effect. A review by Jacob et al20 suggested that it is necessary to make an assessment before the onset of medication. Moreover, evaluations are influenced by age; nevertheless, middle‐ear pathology, which is common in pediatric patients, is a limitation of DPOAE testing.…”

Section: Discussionmentioning

confidence: 99%

Distortion product otoacoustic emission for the screening of cochlear damage in children treated with cisplatin

Al-Noury

2011

The Laryngoscope

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Distortion product otoacoustic emission for the screening of cochlear damage in children treated with cisplatin

Al-Noury

2011

The Laryngoscope

View full text Add to dashboard Cite

show abstract

“…Audiological monitoring should aim to identify the hearing loss early and reduce its impact on the individual's life by means of proper medical and hearing intervention [68]. Prospective audiological evaluations remain the only reliable method for detecting ototoxicity before it becomes symptomatic [69].…”

Section: Methodsmentioning

confidence: 99%

Cisplatin-Associated Ototoxicity: A Review for the Health Professional

Paken

Govender

Pillay

et al. 2016

Journal of Toxicology

102

107

View full text Add to dashboard Cite

Cisplatin is an effective drug used in the treatment of many cancers, yet its ototoxic potential places cancer patients, exposed to this drug, at risk of hearing loss, thus negatively impacting further on a patient's quality of life. It is paramount for health care practitioners managing such patients to be aware of cisplatin's ototoxic properties and the clinical signs to identify patients at risk of developing hearing loss. English peer-reviewed articles from January 1975 to July 2015 were assessed from PubMed, Science Direct, and Ebscohost. Seventy-nine articles and two books were identified for this review, using MeSH terms and keywords such as “ototoxicity”, “cisplatin”, “hearing loss”, and “ototoxicity monitoring”. This review provides an up-to-date overview of cisplatin-associated ototoxicity, namely, its clinical features, incidence rates, and molecular and cellular mechanisms and risk factors, to health care practitioners managing the patient with cancer, and highlights the need for a team-based approach to complement an audiological monitoring programme to mitigate any further loss in the quality of life of affected patients, as there is currently no otoprotective agent recommended routinely for the prevention of cisplatin-associated ototoxicity. It also sets the platform for effective dialogue towards policy formulation and strengthening of health systems in developing countries.

show abstract

“…An audiological monitoring program can avert, to a large extent, the reduced quality of life as a result of hearing loss, as patients on cisplatin chemotherapy can be identified early, counselled, monitored, and managed appropriately through medical and hearing interventions in a logical, systematic, and coherent manner. 54 Prospective audiological evaluations remain the only reliable method for detecting ototoxicity before it becomes symptomatic 55 and a communication problem evident. An ototoxicity monitoring program should involve a health care team comprising of an oncology nurse, oncologists, audiologist, and pharmacist to ensure effective sustainability of such a program, if implemented, with the patient being the central focus, as depicted in Fig.…”

Section: Ototoxicity Monitoringmentioning

confidence: 99%

A Review of Cisplatin-Associated Ototoxicity

et al. 2019

View full text Add to dashboard Cite

Cisplatin, an effective antineoplastic drug used in the treatment of many cancers, has ototoxic potential, thus placing cancer patients, receiving this treatment, at risk of hearing loss. It is therefore important for health care professionals managing these patients to be aware of cisplatin's ototoxic properties and its clinical signs to identify patients at risk of developing a hearing impairment. Eighty-five English peer-reviewed articles and two books, from January 1975 to July 2015, were identified from PubMed, ScienceDirect, and EBSCOhost. An overview of cisplatin-associated ototoxicity, namely its clinical features, incidence rates, molecular and cellular mechanisms, and risk factors, is presented in this article. This review further highlights the importance of a team-based approach to complement an audiological monitoring program in reducing any further loss in the quality of life of affected patients, as there is currently no otoprotective agent routinely recommended for the prevention of cisplatin-associated ototoxicity.

show abstract

Auditory monitoring in ototoxicity

Abstract: we suggest a hearing monitoring protocol, considering the patients capability to respond to behavioral tests and monitoring timing (first test/follow up). For cancer patients, hearing monitoring should be performed in the patients treatment venue.

Cited by 27 publications

References 29 publications

Distortion product otoacoustic emission for the screening of cochlear damage in children treated with cisplatin

Distortion product otoacoustic emission for the screening of cochlear damage in children treated with cisplatin

Cisplatin-Associated Ototoxicity: A Review for the Health Professional

A Review of Cisplatin-Associated Ototoxicity

Contact Info

Product

Resources

About